New Cell Therapy Delivers Cancer Viruses to Tumours

Adults with solid tumours may one day benefit, but the approach has so far been tested only in mouse models.

Updated on Nov. 7, 2026 in Cancer

Bold flat-color editorial illustration of rounded cells drifting along a tissue channel toward a dark mass, carrying glowing payloads across a cream field.
Houston-based FibroBiologics received a European patent for engineering fibroblast cells to deliver cancer-fighting viruses into tumours, though the work has so far been tested only in mice. AI Illustration. Upload story photo >

The European Patent Office has granted European Patent No. EP 4454709 to FibroBiologics Inc., a Houston-headquartered company, covering a method of engineering fibroblasts to home in on cancer cells and carry anti-tumour agents into tumours. The patent's own data are from preclinical mouse studies.

Why it matters

Patients with solid tumours currently depend on treatments that often struggle to reach the tumour directly, so a delivery approach that uses the body's own tendency to recruit fibroblasts to tumours is a new direction in cancer research. The grant protects the technology in Europe, but it does not mean the approach has been shown to work in people.

The supporting data come from a mouse melanoma model described in the patent, not from clinical trials in people. The comparison showed that fibroblast-delivered Newcastle disease virus slowed tumour growth while the virus alone did not.

The players

FibroBiologics Inc.

A Houston-based company developing cell-based therapies that use fibroblasts to deliver anti-tumour agents, holding more than 270 patents and patent applications.

European Patent Office

The regional agency that examines and grants patents across Europe, including those covering biomedical and cancer therapy technologies.

The details

Fibroblasts are connective-tissue cells that naturally migrate toward tumours and become part of the surrounding tissue. In the approach described in the patent, the cells are modified in culture to strengthen their homing toward cancer cells, then conditioned under low-oxygen conditions and loaded with an oncolytic virus, such as vaccinia virus, or other anti-tumour payloads. Once administered, the fibroblasts are intended to carry that payload into the tumour and release it where it is needed.

Timeline

  1. The patent was granted by the European Patent Office, with the publication announcing the grant dated November 7, 2026.

  2. The exact date of the underlying patent grant was not stated in the source.

Health Landscape

Oncolytic viruses are an active area of cancer research because they can selectively infect and destroy tumour cells. This patent proposes a new delivery route, using tumour-homing fibroblasts, to help those viruses reach tumours more effectively.

This development is early-stage and does not change current cancer screening, treatment, or insurance coverage. If you or a family member are facing a cancer diagnosis, the practical step is to discuss available clinical trials and treatment options with your oncologist.

The takeaway

A patent grant confirms the intellectual property behind an experimental approach, but it is not evidence of clinical effectiveness. Patients interested in emerging cancer therapies can ask their oncologist whether a clinical trial may be a suitable option.

Further reading

For more on how new approaches are being tested against tumours, browse our Cancer coverage.

Source note: This article includes information reported by Pharmabiz.